When GLP-1 receptor agonists first emerged as a weight loss tool, even I underestimated them. I’d been practicing internal medicine for years, and I’d seen plenty of “breakthrough” obesity treatments come and go. But the data behind semaglutide and tirzepatide is unlike anything I’ve encountered in metabolic medicine — and I want to explain why.
GLP-1s work by mimicking a hormone your gut naturally releases after eating. They slow gastric emptying, reduce appetite signaling in the brain, and — critically — improve insulin sensitivity at the cellular level. This isn’t just about eating less. It’s a fundamental recalibration of how your body processes energy.
What the headlines often miss is the cardiovascular data. The SELECT trial showed a 20% reduction in major adverse cardiac events in patients on semaglutide, independent of weight loss. We’re now seeing meaningful reductions in inflammatory markers, liver fat, and blood pressure. For patients managing prediabetes or early metabolic syndrome, these medications may represent a genuine disease-modifying opportunity.
At Aquivia Health, we prescribe GLP-1s the way I’ve always believed medicine should be practiced: with a full clinical picture, individualized dosing, and ongoing oversight. Starting a GLP-1 isn’t a transaction — it’s the beginning of a conversation about your long-term metabolic health. That’s the standard I hold myself to, and it’s the standard we’ve built this platform around.
About The Author
